Alzheimer’s
- The therapeutic potential of the endocannabinoid system for Alzheimer’s disease (PubMed)
- Endocannabinoid signalling in Alzheimer’s disease (PubMed)
- A molecular link between the active component of marijuana and Alzheimer’s disease pathology(PubMed)
- Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells (PubMed)
- The Potential Therapeutic Effects of THC on Alzheimer’s Disease (PubMed)
- The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer’s Disease (PubMed)
- Cannabinoids for the treatment of dementia (PubMed)
- Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression (PubMed)
- Cannabidiol: A promising drug for neurodegenerative disorders? (PubMed)
- Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition (PubMed)
- The role of the endocannabinoid system in Alzheimer’s disease: facts and hypotheses (PubMed)
- The role of phytochemicals in the treatment and prevention of dementia (PubMed)
- Cannabinoids for the treatment of dementia (PubMed)
- Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement (PubMed)
- Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic (Pub Med)
- Can Marijuana Prevent Alzheimer’s? (Next Avenue)
- A Molecular Link Between the Active Component of Marijuana and Alzheimer's Disease Pathology (National Institute of Health)
- Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer’s disease (Neuroscience)
- Cannabinoids and Dementia: A Review of Clinical and Preclinical Data (MDPI-Pharmaceuticals)
- Cannabinoids for the treatment of dementia (Review) (The Cochrane Collaboration)
- Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic (Frontiers in Pharmacology)
- Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease (PubMed)
- Δ9-tetrahydrocannabinol for nighttime agitation in severe dementia (Psychopharmacology)
- Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview (MDPI-Molecules)
- Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer’s disease (Neuropharmacology)
- The influence of cannabinoids on generic traits of neurodegeneration (British Journal of Pharmacology)